

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

As rescanning documents *will not* correct images,  
please do not report the images to the  
**Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**

⑯



Europäisches Patentamt  
European Patent Office  
Office européen des brevets

⑯

Publication number:

**0 135 712**  
**A2**

⑯

## EUROPEAN PATENT APPLICATION

⑯ Application number: 84108925.3

⑯ Int. Cl. 4: **C 12 P 21/00, C 12 N 15/00,**  
**C 07 K 15/04, A 61 K 39/012,**  
**C 07 K 3/18**  
**// A61K39/395,**  
**C12N5/00 ,(C12P21/00,**  
**C12R1:91)**

⑯ Date of filing: 27.07.84

⑯ Priority: 19.08.83 US 524819

⑯ Applicant: **AMERICAN CYANAMID COMPANY,**  
**1937 West Main Street P.O. Box 60, Stamford**  
**Connecticut 06904 (US)**

⑯ Date of publication of application: 03.04.85  
Bulletin 85/14

⑯ Inventor: **Schenkel, Robert Harris, 355 Robin Hood Drive,**  
**Yardley Pennsylvania 19067 (US)**  
Inventor: **Wong, Rosie Bick-Har, 16 Ross Hall Boulevard,**  
**Piscataway New Jersey 08854 (US)**  
Inventor: **Thammana, Pallaiah, 8 Village Green Way,**  
**Hazlet New Jersey 07730 (US)**

⑯ Designated Contracting States: **AT BE CH DE FR GB IT**  
**LI LU NL SE**

⑯ Representative: **Wächtershäuser, Günter, Dr., Tel 29,**  
**D-8000 München 2 (DE)**

⑯ **Antigens and monoclonal antibodies reactive against sporozoites of eimeria spp.**

⑯ **Monoclonal antibodies against sporozoites of the Eimeria spp. are obtained by use of hybridoma technology. Specific sporozoite antigens for use as vaccines in the prevention and treatment of coccidiosis and hybridoma cultures producing monoclonal antibodies are described.**

**EP 0 135 712 A2**

ANTIGENS AND MONOCLONAL ANTIBODIES REACTIVE  
AGAINST SPOROZOITES OF THE *Eimeria* spp.

5       The invention herein described relates to monoclonal antibodies which react specifically against sporozoites of the parasite *Eimeria tenella*. Hybridoma cultures producing antibodies against *E. tenella* are described. Such antibodies are obtained by means of hybridoma technology. Sporozoite antigens are identified  
10      and characterized. These antigens, along with certain monoclonal antibodies are effective for the prevention and treatment of coccidiosis. The antigens of the invention are useful as vaccines against coccidiosis.

15      By way of background, coccidiosis is a disease of animals caused by a variety of protozoan parasites. Avian coccidiosis is a devastating disease of poultry caused by a variety of species of the genus *Eimeria*. This disease has a complicated life cycle consisting of both asexual and sexual stages. Chickens are initially  
20      infected with the disease after ingestion of free-living oocysts which are generally associated with fecal material. Oocysts develop into invasive asexual sporozoites in the chicken's digestive tract. The sporozoites infect epithelial cells and develop into multinucleate structures known as schizonts. Each schizont matures and eventually liberates multiple invasive asexual structures known as merozoites. These merozoites leave the infected cell and reinvoke other

-2-

epithelial cells. The multiple invasive asexual stages involving sporozoites and merozoites account for much of the pathology of coccidiosis. The sexual cycle of coccidiosis is initiated when merozoites differentiate into gametocytes. Fertilization occurs and the 5 fertilization products known as oocysts are released in the feces. Thus the parasite's life cycle is completed. In chickens, the life cycle of Eimeria tenella, a representative species, is completed in about 7 to 9 days.

10 Due to the tremendous economic losses inflicted on the poultry industry by Eimeria species, a vaccine against the parasite is highly desirable. However, due to the complexity of the life cycle of the parasite and the variability of the quantity of antigens present in each stage, it has been observed that deactivated or 15 killed parasites have not generated consistent immunity in the past. One solution to this problem is to isolate and characterize particular antigens from the parasite and administer them in a sufficient amount to serve as an immunizing agent. Preferably such antigens will offer protection against infection by all important species. It is known that various species of Eimeria, as well as 20 different stages in the life cycle of the same species, have both common and specific antigens [Cerna, Z., Folia Parasitologica (Prague) 17:135-140 (1970); Davis et al., Immunol. 34:879-888 (1978); Rose, M.E., Immunol. 25 2:112-122 (1959); Rose et al., Immunol. 5:79-92 (1962); and Tanielian et al., Acta Parasitol. Jugosl. 7:79-84 (1976)]. It is also known that development of immunity to Eimeria is species specific and in some species of 30 domestic fowl there is significant strain-specific immunity [Jeffers, T.K.; In Long, P.L. et al. (eds.), Avian Coccidiosis, pp. 57-125, Proc. 13th Poultry Sci. Symp. (1978); Joyner, L.P., Parasitol. 59:725-732 (1969);

Long, P.L., Parasitol. 69:337-347 (1974); and Long et al., Parasitol. 79:451-457 (1979)]. Currently immunogens of Eimeria species capable of stimulating protective immunity in avian or mammalian hosts have not yet been isolated or identified. Such Eimeria immunogens will likely provide successful immunization against coccidiosis.

The development of lymphocyte hybridoma technology provides a tool for producing relatively large amounts of specific antibodies against various antigens of Eimeria. By fusing specific antibody-producing cells (spleen cells) with cells of a myeloma tumor, it is possible to produce hybridoma cells that secrete monoclonal antibodies directed specifically against the original sensitizing antigen. [Köhler & Milstein, Nature (London) 256:495-497 (1975)]. If monoclonal antibodies against the parasite are obtained, it may be possible to provide such antibodies to infected or susceptible fowl and to thus provide the host organism with a measure of passive immunity. Once such hybridoma cultures producing monoclonal antibodies are obtained, it is possible by various procedures to utilize such antibodies to isolate and identify specific antigens which could in turn be utilized as a vaccine to provide host organisms with a system of active immunity. Various patents concerning hybridoma cultures and monoclonal antibodies are known (i.e., U.S. Pat. Nos. 4,172,124; 4,196,265; 4,271,145; 4,361,549; 4,631,550; 4,364,932; 4,364,933; 4,364,934; 4,364,935; 4,364,936; 4,381,292; and 4,381,295).

In light of the foregoing discussion of the economic effects of coccidiosis in the area of animal husbandry and more specifically in the poultry industry

-4-

control of the protozoan parasite Eimeria is highly desirable. Accordingly, an object of this invention is to provide new and useful monoclonal antibodies obtained against sporozoites of the genus Eimeria. A further object is to isolate and identify specific antigens of E. tenella useful as a vaccine for the control of avian coccidiosis. These objects are manifest in the following description and particularly delineated in the appended claims.

5 A preparation of E. tenella sporozoites is used to immunize mice in order to eventually generate monoclonal antibodies following the method of Köhler and Milstein as described below. The monoclonal antibodies are used to identify antigens of the parasite. The antigens which elicit monoclonal antibodies that react with sporozoites, and show neutralization of parasite growth, are considered protective antigens. The protective antigens that occur in various species of Eimeria are regarded as potential candidates for the development 10 of a vaccine against avian coccidiosis.

15 Soluble antigens are obtained from sporozoites of E. tenella. These soluble antigens are separated electrophoretically by molecular weight and those which specifically react with monoclonal antibodies of the present invention are identified. Using appropriate 20 standards, the reactive antigens are then characterized 25 on the basis of molecular weight.

25 In order to evaluate the ability of the monoclonal antibodies to effectively neutralize the infective capability of coccidial sporozoites, chickens are exposed 30 to sporozoites of E. tenella previously treated with various monoclonal antibodies of the invention. This in vivo experimental system demonstrates the protective 35 capabilities of selected monoclonal antibodies.

-5-

Chickens receiving injections of solubilized sporozoite antigens including those identified by the corresponding monoclonal antibodies were found to be protected against oral challenge. This immunization procedure demonstrates the vaccine potential of sporozoite antigens which can be recognized by monoclonal antibodies.

The following non-limiting Examples further serve to illustrate the invention:

EXAMPLE 1

Construction of Hybridoma Lines

Sporozoites of the organism Eimeria tenella are obtained by excysting sporulated oocysts using established procedures [Doran et al., Proc. Helmintol. Soc. Wash. 34:59-65 (1967)]. A preparation of E. tenella sporozoites thus obtained is used to immunize eighteen-week-old female BALB/c mice by intraperitoneal injection. After determining that an immunized mouse is producing anti-sporozoite antibodies using an indirect immunofluorescence assay (IFA) technique known to the art, spleen cells are obtained from the mouse and fused with mouse myeloma cell line P3X63. Ag8.653. The fusion process is carried out in the presence of 30 to 35% polyethylene glycol (950-1050). The method of generating hybridomas has been previously described (c.f., Kennett et al., Monoclonal Antibodies - Plenum Press: 365-371, 1980). Hybridoma fusion products are cultured in HAT medium [Littlefield, J.W., Science, 145:709-710 (1964)] containing Iscove's modified Dulbecco's medium (IMDM) with 20% fetal calf serum supplement. Culture media are monitored for anti-sporozoite antibody production by indirect immunofluorescence assay (IFA) using glutaraldehyde fixed sporozoites of E. tenella as the antigen source. Of all the cultures tested, 33 wells were found positive by IFA.

In order to ensure monoclonality of the hybridoma cultures, a limiting dilution procedure was employed. Following exposure of E. tenella sporozoites to various monoclonal antibodies of the invention, three major IFA reactivity patterns on treated sporozoites are observed: (1) reaction on the entire surface of sporozoites; (2) surface reaction as patches on the sporozoites; (3) internal reaction around the nuclear membranes of sporozoites. These reaction patterns are confirmed by ferritin labelling and transmission election microscopy (Speer *et al.*, *J. of Protozoology* in press). As assessed by IFA, hybridoma cultures of the invention generate identical antibodies after cloning. Clones are grown either *in vitro* or in BALB/c mice as peritoneal tumors and the ascites fluid contains antibodies in a concentration of up to approximately 10 mg/ml.

#### EXAMPLE 2

##### Preparation of Antigens Associated with E. tenella sporozoites

Freshly excysted sporozoites of E. tenella are used for the antigen preparation. The outer membrane components of the sporozoites are extracted using detergents (i.e., 0.5% Nonidet P40, 0.5 to 2% CHAPS, or 0.5% to 1% Triton X-100) in 5 mM sodium phosphate buffer having a pH of 7.8. The buffer contains the following protease inhibitors: aprotinin (2 trypsin units/ml); antipain (25 µg/ml); leupeptin (25 µg/ml), phenyl methyl sulfonyl fluoride (4 mM) [Yoshida *et al.*, *J. Exp. Med.*, 154:1225- 1236 (1981)]. The detergent solubilized material is centrifuged at 100,000 x g for 10 minutes to remove particulate matter. The clear supernatant contains soluble antigens associated with E. tenella sporozoites.

EXAMPLE 3Antigen Characterization

Soluble antigens of E. tenella sporozoites are separated by molecular weight using SDS polyacrylamide gel electrophoresis (PAGE) [Laemmli, U.K., *Nature* 227: 680-685 (1970)]. The SDS PAGE separated proteins are transferred electrophoretically onto nitrocellulose membranes using the Western blotting technique [Towbin et al., *Proc. Natl. Acad. Sci. (USA)* 76:4350-4354 (1979)]. The nitrocellulose filter is then reacted with either diluted ascites fluid or spent hybridoma culture fluid containing antibodies. Bound monoclonal antibodies are then detected by using a radioimmuno detection method involving  $^{125}\text{I}$  labelled anti-mouse IgG antibody (New England Nuclear). The unbound second antibody is removed by washing, and the nitrocellulose filters are then exposed with Kodak X-ray film XAR-5.

Alternatively, specific antigen-monoclonal antibody complexes are identified by an ELISA technique using horseradish peroxidase coupled rabbit IgG antibody (Cappel Lab) against mouse immunoglobulin [Burnette et al., *Anal. Biochem.* 112:195-203 (1981)]. The Bio-Rad Immuno Blot Assay Kit is employed.

The apparent molecular weights of the reactive sporozoite antigens are determined by comparing the electrophoretic Rf values of the antigens with Rf values of known molecular weight compounds run as standards along with the antigens in the same system. The experimental molecular weight data of various antigens are presented in Table I.

0135712

-8-

TABLE I  
MOLECULAR WEIGHT DETERMINATION OF  
VARIOUS E. TENELLA SPOROZOITE ANTIGENS

	<u>Hybridoma Culture</u>	<u>Monoclonal Antibody</u>	<u>Approximate Molecular Weight of Antigen</u>
5	s5E5	s1	110 $\pm$ 16, 130 $\pm$ 20 kd
	s4E2	s2	110 $\pm$ 16, 130 $\pm$ 20 kd
10	s1C4	s3	66 $\pm$ 9 kd, 55 $\pm$ 8 kd, 20 - 30 kd, 18 $\pm$ 3 kd, 15 $\pm$ 2 kd
	s2G8	s4	55 $\pm$ 8 kd
15	s5B9	s5	55 $\pm$ 8 kd
	s1A	s6	54 $\pm$ 8 kd
20	s3C11	s7	50 $\pm$ 7 kd
	s3D3	s8	29 $\pm$ 4 kd
	s1E4	s9	58 $\pm$ 9 kd, 130 $\pm$ 20 kd

-9-

EXAMPLE 4

Neutralization of Sporozoites of *E. tenella*  
With Monoclonal Antibodies Using  
In Vivo Chicken Assay

5 An in vivo system is employed to evaluate the capability of monoclonal antibodies produced from hybridoma lines of the invention to neutralize sporozoites of *E. tenella*. The caeca of the fowl are the sites of infection by *E. tenella* and are accessible by surgery [Burns et al., *Exp. Parasitol.* 8:515-526 (1959); Lawn et al., *J. Parasitol.* 68:1117-1123 (1982)]. The caeca of chickens are surgically exposed and infused with preparations of *E. tenella* sporozoites which have been previously treated with monoclonal antibodies of the invention.

10 15 Freshly excysted sporozoites are incubated under sterile conditions with heat inactivated ascites fluid containing monoclonal antibodies derived from hybridoma lines of the invention. The incubation period is for 30 to 60 minutes at 25° to 37°C. An incubation period of 37°C for 60 minutes is preferred. Treated sporozoites are then introduced into the caeca of three-week-old chickens by surgical procedures. At the end of a five-day incubation period, the caeca of the infected chickens are observed for lesions. The five-day incubation period represents the most destructive stage of coccidiosis. Results of this experiment are presented in Table II. It is noted that monoclonal antibodies s3 and s8 both provided 60% total protection against infection by sporozoites of *E. tenella*.

20 25 30

0135712

-10-

**TABLE II**  
**IN VIVO EVALUATION OF VARIOUS MONOCLONAL ANTIBODIES FOR THE CONTROL OF SPOROZOITES OF *E. TENELLA***

Treatment	Hybridoma Line (source of monoclonal antibody)	Monoclonal Antibody No.	Number of Sporozoites	% Protection		
				None	Partial	Complete
---	---	---	2000	70	21	9
s3D3	s8	s8	2000	30	10	60
s2G8	s4	s4	2000	100	0	0
s1C4	s3	s3	2000	20	20	60
s1E4	s9	s9	2000	60	0	40
s3D3 & s2G8	s8 + s4	s8 + s4	2000	25	19	56
s3D3 & s1C4	s8 + s3	s8 + s3	2000	75	0	25
---	---	---	3000	89	11	0
s3D3	s8	s8	3000	60	40	0
s2G8	s4	s4	3000	67	16	16
s1C4	s3	s3	3000	50	0	50
s1E4	s9	s9	3000	100	0	0
s3D3 & s2G8	s8 + s4	s8 + s4	4000	50	50	0
s3D3 & s1C4	s8 + s3	s8 + s3	3000	50	0	50
s3D3 & s1A	s8 + s6	s8 + s6	3000	80	0	20

EXAMPLE 5Immunization with *E. tenella* sporozoite antigens

Chickens at one week of age were immunized  
 5 intraperitoneally with solubilized *E. tenella* sporozoite  
 antigens. Initial injections employed proteinaceous  
 material derived from  $1.5 \times 10^7$  sporozoites in Freund's  
 complete adjuvant. Two boosters followed at ten-day  
 intervals each employing one-half the initial immunizing  
 10 dose of material in Freund's incomplete adjuvant. Ten  
 days after the last booster, the chickens were challenged  
 with 50,000 oocysts orally. Five days post-challenge,  
 caecal lesions were observed. Results on this experiment  
 are presented in Table III. It is noted that soluble  
 15 antigens render significant protection against oral  
 oocyst challenge whereas normal chickens are not protected.

TABLE III

20	<u>Treatment</u>	<u>Percent protection (% of birds tested)</u>		
		<u>None</u>	<u>Partial</u>	<u>Complete</u>
	Control	100	0	0
	Immunized	0	33	66

25 The new monoclonal antibodies, No. s1C4, No.  
 s3D3, No. s1E4, No. s5B9, No. s5E5, No. s1A and No.  
 s2G8, isolated as described hereinabove, have been  
 deposited with the American Type Culture Collection  
 30 (ATCC) located in Rockville, Maryland and have been  
 added to its permanent collection. No. s1C4 has been  
 assigned the number HB8333; No. s3D3 has the number  
 HB8331, No. s1E4 has been designated the number HB8332,  
 No. s5B9 has been designated number HB8402, No. s5E5 has  
 35 been designated number HB8403, No. s1A has been designated  
 number HB8404 and No. s2G8 has been designated  
 number HB8405. Access to the antibodies are available  
 during the pendency of the present application to one  
 determined by the Commissioner of Patents and Trademarks

0135712

- 12 -

to be entitled thereto under 37 C.F.R. 1.14 and 35 U.S.C. 122,  
and all restrictions on the availability to the public of  
HB8331, HB8332, HB8333, HB8402, HB8403, HB8404 and HB8405  
will be irrevocably removed upon the granting of a patent on  
5 the present application.

No. s1C4, HB8333, No. s3D3, HB8331 and No. s1E4, HB8332  
were deposited with the ATCC on August 11, 1983. The new  
monoclonal antibodies No. s5B9, HB8402, No. s5E5, HB8403, No.  
s1A, HB8404 and No. s2G8, HB8405 were deposited with the ATCC  
10 on November 1, 1983.

15

20

25

30

35

## WHAT IS CLAIMED IS:

1. Monoclonal antibodies produced by hybridomas formed by fusion of cells from a mouse myeloma line and spleen cells from a mouse previously immunized with Eimeria tenella sporozoites which antibody:

- (a) reacts specifically with antigens of Eimeria spp. sporozoites
- (b) reacts specifically with antigens of Eimeria tenella having a molecular weight of approximately 13 to 150 kd.

2. Monoclonal antibodies according to Claim 1 which are produced from hybridomas formed by fusion of P3x63.Ag8.653 myeloma cells and spleen cells from BALB/c mice previously immunized with E. tenella sporozoites.

3. A monoclonal antibody according to Claim 2 which is produced by the hybridoma designated clone number s5E5 and deposited as ATCC No. HB8403; which is produced by the hybridoma designated clone number s4E2; which is produced by the hybridoma designated clone No. s1C4 and deposited as ATCC No. HB8333; which is produced by the hybridoma designated clone No. s2G8 and deposited as ATCC No. HB8405; which is produced by the hybridoma designated clone No. s5B9 and deposited as ATCC No. HB8402; which is produced by the hybridoma designated clone No. s1A and deposited as ATCC No. HB8404; which is produced by the hybridoma designated clone No. s3C11; which is produced by the hybridoma designated clone No. s3D3 and deposited as ATCC No. HB8331; or which is produced by the hybridoma designated clone No. s1E4 and deposited as ATCC No. HB8332.

4. The monoclonal antibody which reacts with antigens of Eimeria tenella sporozoites prepared by the method which comprises the steps of:

- (a) immunizing mice with E. tenella sporozoites;
- (b) removing the spleens from said mice and making a suspension of the spleen cells;
- (c) fusing said spleen cells with mouse myeloma cells in the presence of a fusion promotor;

- (d) diluting and culturing the fused cells in separate wells in a medium which will not support the growth of unfused myeloma cells;
- (e) evaluating the supernatant of each well containing a hybridoma for the presence of antibody reactive with E. tenella sporozoites;
- (f) selecting and cloning a hybridoma producing antibody reactive with E. tenella sporozoites; and
- (g) recovering the antibody from the supernatant or ascitic product of said clones.

5. A method of preparing monoclonal antibodies which react with antigens of Eimeria spp. sporozoites which comprises culturing clone No. s5E5 (ATCC No. HB8403), s4E2, s1C4 (ATCC No. HB8333), s2G8 (ATCC No. HB8405), s5B9 (ATCC No. HB8403), s1A (ATCC No. HB8404), s3C11, s3D3 (ATCC No. HB8331), or s1E4 (ATCC NO. HB8332), in a suitable medium and recovering the antibody from the supernatant of an above said hybridoma culture; or which comprises injecting into a mouse a hybridoma culture designated clone No. s5E5 (ATCC No. HB8403), s4E2, s1C4 (ATCC No. HB8333), s2G8 (ATCC No. HB8405), s5B9 (ATCC No. HB8402), s1A (ATCC No. HB8404), s3C11, s3D3 (ATCC NO. HB8331), or s1E4 (ATCC No. HB8332) and recovering said antibody from the ascites or serum of said mouse.

6. A monoclonal antibody prepared by each of the methods of Claim 5.

7. An antigenic, immunogenic, proteinaceous vaccine which is soluble in detergent containing buffer present an an antigen of Eimeria tenella sporozoites, specifically reactive with anti-sporozoite monoclonal antibodies secreted by hybridoma clones s5E5 (ATCC No. HB8403) and having molecular weights of  $110 \pm 16$  kd and  $130 \pm 20$  kd; specifically reactive with anti-sporozoite monoclonal antibodies secreted by hybridoma clone s4E2 and having molecular weights of  $110 \pm 16$  kd and  $130 \pm$  kd; specifically reactive with anti-sporozoite monoclonal anti-

- 15 -

bodies secreted by hybridoma clone s1C4 (ATCC No. HB8333), and having molecular weights of  $66 \pm 9$  kd,  $55 \pm 8$  kd, 20 - 30 kd,  $18 \pm 3$  kd,  $15 \pm 2$  kd; specifically reactive with anti-sporozoite monoclonal antibodies secreted by hybridoma clone s2G8 (ATCC No. HB8405) and having molecular weight of  $55 \pm 8$  kd; specifically reactive with anti-sporozoite monoclonal antibodies secreted by hybridoma clone s5B9 (ATCC No. HB8402) and having molecular weight of  $55 \pm 8$  kd; specifically reactive with anti-sporozoite monoclonal antibodies secreted by hybridoma clone s1A (ATCC No. HB8404) and having molecular weight of  $54 \pm 8$  kd; specifically reactive with anti-sporozoite monoclonal antibodies secreted by hybridoma clone s3C11 and having molecular weight of  $50 \pm 7$  kd; specifically reactive with anti-sporozoite monoclonal antibodies secreted by hybridoma clone s3D3 (ATCC No. HB8331), and having a molecular weight of  $29 \pm 4$  kd; or specifically reactive with anti-sporozoites monoclonal antibodies secreted by hybridoma clone s1E4 (ATCC No. HB8332), and having molecular weights of  $58 \pm 9$  kd and  $130 \pm 20$  kd.

8. A vaccine according to Claim 7 additionally comprising a stabilizer and/or pharmaceutically acceptable adjuvant therefor.

9. An antigen vaccine according to Claim 7 prepared by the steps of:

- (a) extracting, and solubilizing sporozoite antigens of E. tenella;
- (b) separating the solubilized material by routine isolation and purification methods including but not limited to chromatography and affinity column methodology to obtain purified antigen.

10. A method of combating Eimeria spp. infection which comprises exposing domestic species to one or a combination (mixture) of antigens identified by monoclonal antibodies of the invention.